Who classification and advances in epithelial ovarian tumor and small cell carcinoma of ovary, complete classification of ovarian tumors Pathogenesis morphology md pathology 10 marks

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Searching Images

ovarian serous cystadenocarcinoma gross microscopy histology

Reading File

Searching Images

ovarian tumor gross morphology serous mucinous cystic

This is a gross pathology photograph of an ovarian tumor. The specimen represents a unilateral ovarian mass with multilocular cystic architecture. The internal content consists of clear, colorless serous fluid within multiple thin-walled cysts. The cyst walls are smooth and translucent, without obvious mural nodules or solid components on gross examination. The external surface is pale, smooth, and without frank hemorrhage or necrosis. The overall appearance is consistent with a benign serous cystadenoma of ovarian origin. The lesion is located in the pelvis, arising from the ovarian surface or cortical epithelium, and demonstrates a predominately cystic, noninfiltrative growth pattern. The patient is a 38-year-old female; serous cystadenomas are common epithelial ovarian neoplasms and typically present as enlarging adnexal masses or incidental findings. Diagnostic significance: gross features favor a benign process, but histopathologic confirmation is essential to exclude serous cystadenocarcinoma or mucinous variants. Differential considerations include mucinous cystadenoma/cystadenocarcinoma, serous borderline tumors, and paraovarian cysts. Clinical correlation: complete surgical excision with intact capsule provides definitive treatment and favorable prognosis. Potential clinical use cases: educational reference for ovarian tumor morphology, gross-pathology catalogs, radiologic-pathologic correlation studies, and machine learning datasets for ovarian neoplasms. This image supports differential diagnosis and educational training in gynecologic pathology.

Gross pathology image of bilateral ovarian neoplasms from a surgical resection specimen. The top ovary displays a Brenner tumor with a yellow-white solid cut surface, a feature consistent with fibrous stroma and epithelial nests seen on histology but evident here in gross form. The bottom ovary shows a mucinous cystadenoma manifesting as a multilocular cystic mass with a gleaming, mucoid inner surface. A conspicuous solid yellowish nodule is noted within the mucinous component, adding a focal solid element to the otherwise cystic lesion. The external surfaces show typical ovarian morphology; cross-sectioning reveals distinct tumor components in a single image field, illustrating a concurrent benign Brenner tumor and benign mucinous cystadenoma in two ovaries. This composite ovarian tumor presentation is recognized in gynecologic pathology as an ovarian collision or coexistence of histologically distinct neoplasms, with Brenner tumor arising from transitional-type epithelium in fibrous stroma and mucinous cystadenoma arising from mucinous epithelium. Clinically, these lesions are usually benign; definitive classification requires histopathology, but gross appearance supports benign behavior. Potential differential diagnoses include mucinous cystadenocarcinoma, serous cystadenoma/carcinoma, and urothelial-like (transitional) lesions. The image is intended for educational purposes and correlates with gross anatomy, tumor morphology, adnexal pathology, and surgical pathology workflows, enhancing recognition of mixed ovarian neoplasm patterns in teaching datasets and libraries.

This gross pathology image depicts a unilateral ovarian tumor measuring 12 cm, displaying both solid and cystic components. Cysts are filled with serous fluid and are partially lined by papillary proliferations; scattered necrotic foci are evident within the parenchyma. The specimen demonstrates classic features of a malignant epithelial ovarian tumor of serous type, specifically serous papillary cystadenocarcinoma, as described in the accompanying diagnosis. The outer surface is irregular with friable, yellow-tan tissue and focal hemorrhagic areas; cross-sectional areas reveal multilocular cystic spaces interspersed with solid nodules. In a 69-year-old female, these macroscopic findings correlate with advanced-age onset ovarian carcinoma and may reflect high-grade disease. This image is suitable for educational illustrating the gross morphology of serous ovarian carcinoma, including papillary architecture, cystic dilation, necrosis, and a mix of solid and cystic tumor burden. The specimen highlight underscores the importance of comprehensive macroscopic examination as part of surgical pathology workflows, aiding staging and guiding histologic sampling. Pathoanatomic correlation with microscopic serous papillary carcinoma features—papillary fronds, atypia, mitotic activity—requires histology. Used clinically, such gross images support tumor identification, differential diagnosis from serous cystadenoma or mucinous tumors, and are valuable for medical education and tumor registries. Image credit: pathorama.ch.

I now have all the material needed for a comprehensive 10-mark MD Pathology answer. Let me compile it.

Ovarian Tumors: WHO Classification, Epithelial Tumors, and Small Cell Carcinoma

(MD Pathology - 10 Marks)

I. WHO CLASSIFICATION OF OVARIAN NEOPLASMS (Table 22.3 - Robbins, Cotran & Kumar)

Based on the most probable tissue of origin, ovarian neoplasms arise from three main components:

Surface/fallopian tube epithelium and endometriosis
Germ cells (from yolk sac, pluripotent)
Stromal cells (sex cord cells, endocrine precursors)

A. SURFACE EPITHELIAL-STROMAL TUMORS (~65% of all ovarian tumors)

Tumor Type	Benign	Borderline	Malignant
Serous tumors	Cystadenoma, cystadenofibroma	Serous borderline tumor	Low-grade & high-grade serous adenocarcinoma
Mucinous tumors (endocervical-like & intestinal type)	Cystadenoma, cystadenofibroma	Mucinous borderline tumor	Mucinous adenocarcinoma
Endometrioid tumors	Cystadenoma, cystadenofibroma	Endometrioid borderline tumor	Endometrioid adenocarcinoma
Clear cell tumors	Benign	Borderline	Clear cell adenocarcinoma
Brenner tumors	Benign Brenner tumor	Borderline Brenner tumor	Malignant Brenner tumor
Epithelial-stromal	-	-	Adenosarcoma, Carcinosarcoma

B. SEX CORD-STROMAL TUMORS (~8% of ovarian tumors)

Granulosa cell tumors
Fibromas / Fibrothecomas / Thecomas
Sertoli-Leydig cell tumors
Steroid (lipid) cell tumors

C. GERM CELL TUMORS (~15-20% of ovarian tumors)

Teratoma: Immature | Mature (solid / cystic - dermoid cyst) | Monodermal (struma ovarii, carcinoid)
Dysgerminoma
Yolk sac tumor
Mixed germ cell tumors

D. METASTATIC TUMORS TO OVARY (~5%)

Colonic, appendiceal
Gastric (Krukenberg tumor - signet ring cell type)
Breast, endometrial, cervical

II. FREQUENCY OF MAJOR OVARIAN TUMORS (Table 22.4 - Robbins)

Type	% of Malignant Ovarian Tumors	% Bilateral
Serous	47%	Benign 25%, Borderline 30%, Malignant 65%
Mucinous	3%	Benign 5%, Borderline 10%, Malignant <5%
Endometrioid carcinoma	20%	40%
Undifferentiated carcinoma	10%	-
Clear cell carcinoma	6%	40%
Granulosa cell tumor	5%	5%
Teratoma	1%	Rare (benign)
Metastatic	5%	>50%

III. EPITHELIAL OVARIAN TUMORS - DETAILED CLASSIFICATION & PATHOGENESIS

General Features

About 80% of ovarian tumors are benign, mostly in women aged 20-45 years. Borderline tumors occur at slightly older ages. Malignant tumors are commonest between 45-65 years. Ovarian cancer accounts for 3% of cancers in females and is the 5th most common cancer death in women in the USA.

Most primary ovarian neoplasms arise from Müllerian epithelium. Classification is based on:

Differentiation of neoplastic epithelium (serous, mucinous, endometrioid)
Extent of epithelial proliferation (benign, borderline, malignant)

Pathogenesis - Molecular Advances (Type I vs Type II Paradigm)

Robbins notes that different morphologic types harbor distinct but overlapping genetic alterations. The modern dualistic model divides ovarian carcinomas into:

Feature	Type I (Low-grade)	Type II (High-grade)
Precursor	Borderline tumor	STIC (serous tubal intraepithelial carcinoma) in fallopian tube
Behavior	Slow-growing, indolent	Aggressive, rapid
Examples	Low-grade serous, mucinous, clear cell, endometrioid, Brenner	High-grade serous carcinoma (HGSC), carcinosarcoma
Key mutations	KRAS, BRAF, ERBB2, PIK3CA, PTEN, ARID1A	TP53 (>96%), BRCA1/BRCA2
Chromosomal instability	Low	High

Key molecular findings:

High-grade serous carcinoma (HGSC): TP53 mutations in virtually all cases; BRCA1/BRCA2 germline or somatic mutations in 15-25%; most arise from the fallopian tube fimbria (STIC), not the ovarian surface
Low-grade serous: KRAS/BRAF mutations; arise from serous borderline tumors
Endometrioid and clear cell: ARID1A, PIK3CA mutations; arise in a background of endometriosis
Mucinous: KRAS mutations; often arise from Brenner tumors or teratomas

A. SEROUS TUMORS (Most Common Epithelial Type - 47%)

Pathogenesis

Benign/borderline: arise from ovarian surface epithelium invaginations (inclusion cysts) or directly from Müllerian-type epithelium; modern evidence points to fallopian tube origin for many
Malignant (HGSC): now considered to originate primarily from the distal fallopian tube fimbria as STIC lesions, secondarily involving the ovary

Morphology

Benign Serous Cystadenoma:

Most common ovarian neoplasm
Grossly: thin-walled, unilocular or multilocular cyst filled with clear serous fluid; smooth inner lining
Microscopically: single layer of ciliated tubal-type epithelium lining the cyst; minimal atypia
25% are bilateral

Serous Borderline Tumor (Atypically Proliferating Serous Tumor):

Grossly: papillary projections on internal surface; partially solid
Microscopically: epithelial stratification, nuclear atypia, mitoses, but NO stromal invasion - the key diagnostic criterion
30% bilateral
Favorable prognosis; rare progression to carcinoma

High-Grade Serous Carcinoma (Malignant):

Most common cause of ovarian cancer death
Grossly: partly solid, partly cystic with extensive papillary excrescences; friable, yellow-tan with necrosis and hemorrhage; frequently bilateral (65%)
Microscopically: papillary, glandular, or solid architecture; highly pleomorphic cells; numerous mitoses; psammoma bodies (concentric calcifications - characteristic); TP53 mutation present in >96%
Spreads transcoelomically to peritoneum, omentum (omental cake), bowel serosa

Serous papillary cystadenocarcinoma - solid and cystic components with papillary growth and necrosis

B. MUCINOUS TUMORS (3% of malignant ovarian tumors)

Morphology

Benign Mucinous Cystadenoma:

Grossly: large, multilocular cysts filled with thick, viscid mucinous material; smooth capsule; can reach enormous size (up to 50 kg reported)
Microscopically: lined by tall columnar mucin-secreting cells resembling endocervical (Müllerian type) or intestinal epithelium (goblet cells)
80% benign; 5% bilateral

Borderline Mucinous Tumor:

Microscopically: epithelial stratification, tufting, nuclear atypia; NO invasion

Mucinous Adenocarcinoma:

Grossly: partly solid areas within multiloculated cysts
Microscopically: glandular structures with obvious stromal invasion; malignant mucinous cells
Must be distinguished from metastatic colonic adenocarcinoma (Krukenberg) - CK7+/CK20- favors primary ovarian

Pseudomyxoma peritonei: Massive accumulation of mucinous material in peritoneal cavity - usually arises from appendiceal mucinous neoplasm (NOT primary ovarian)

C. ENDOMETRIOID TUMORS (20% of malignant ovarian tumors)

Pathogenesis: strongly associated with endometriosis; ARID1A mutations, PIK3CA mutations
15-20% occur simultaneously with endometrial carcinoma (synchronous primaries)
Grossly: partly solid and cystic; brown "chocolate" cyst contents if arising from endometrioma
Microscopically: glands resembling proliferative endometrium; tubular glands lined by stratified non-mucinous cells; often squamous differentiation (squamous metaplasia)
40% bilateral

D. CLEAR CELL CARCINOMA (6% of malignant tumors)

Pathogenesis: arises from endometriosis; ARID1A mutations
Grossly: partly solid, partly cystic
Microscopically: cells with abundant clear (glycogen-rich) cytoplasm arranged in solid sheets, tubular or papillary patterns; "hobnail" cells projecting into cystic spaces
Relatively resistant to platinum chemotherapy; worse prognosis than endometrioid

E. BRENNER TUMOR (Transitional Cell Tumor)

Mostly benign; rare borderline and malignant forms
Grossly: solid, fibrous, whitish-grey appearance; often small, incidental
Microscopically: nests of transitional (urothelial-like) epithelium embedded in dense fibrous stroma; cells resemble Walthard cell rests; characteristic "coffee bean" nuclei (nuclear grooves)
Often coincides with mucinous cystadenoma in the same or contralateral ovary

Brenner tumor (yellow-white solid) adjacent to mucinous cystadenoma (multilocular cystic)

IV. ADVANCES IN EPITHELIAL OVARIAN TUMORS

Fallopian tube origin of HGSC: The current consensus is that most HGSC arise from serous tubal intraepithelial carcinoma (STIC) in the fimbria, not the ovarian surface epithelium. This has changed surgical prophylaxis strategy - bilateral salpingectomy is now considered for risk reduction even in average-risk women.
Dualistic carcinogenesis model (Type I vs Type II - see above): completely revised understanding of pathogenesis; Type I low-grade tumors have a stepwise progression through borderline stages with specific driver mutations; Type II HGSC has massive chromosomal instability from the outset.
BRCA1/BRCA2 testing: Germline or somatic BRCA1/BRCA2 mutations are found in 15-25% of HGSC. This predicts sensitivity to PARP inhibitors (olaparib, niraparib, rucaparib) - now used as maintenance therapy after platinum-based chemotherapy.
Homologous recombination deficiency (HRD) is a broader biomarker; tumors with HRD respond to platinum and PARP inhibitors even without BRCA mutations.
Bevacizumab (anti-VEGF): approved for frontline and recurrent ovarian cancer, exploiting the angiogenic dependency of HGSC.
Molecular subtypes of HGSC: The TCGA (The Cancer Genome Atlas) identified four molecular subtypes of HGSC - immunoreactive, differentiated, proliferative, and mesenchymal - with prognostic implications.

V. SMALL CELL CARCINOMA OF THE OVARY (SCCO)

Two distinct types exist:

A. Hypercalcemic Type (SCCOHT) - More Common

Epidemiology:

Average age at diagnosis: 24 years (range 2-46 years); young women and adolescents
Typically unilateral
~2/3 have paraendocrine hypercalcemia (accounts for 50% of all hypercalcemia associated with ovarian tumors)
~50% have spread beyond the ovary at diagnosis

Pathogenesis - Key Advance:

Characterized by germline or somatic mutations in SMARCA4 (SWI/SNF chromatin remodeling gene)
Similar SMARCA4 mutations found in rhabdoid tumors at other sites
It is now proposed that SCCOHT be reclassified as ovarian rhabdoid tumors and treated as such

Morphology:

Grossly: large solid unilateral mass, often with areas of hemorrhage and necrosis
Microscopically: small cells with scanty cytoplasm and hyperchromatic nuclei in diffuse sheets; variable large cell component with prominent nucleoli in ~50%; IHC shows loss of SMARCA4 (BRG1) expression - a diagnostic marker
IHC distinguishes from lymphoma, leukemia, sarcoma

Prognosis: Poor; most patients die within 2 years despite treatment

Management:

Surgery + platinum-based chemotherapy ± radiation
Aggressive combination chemotherapy regimens (as used for rhabdoid tumors) may be beneficial
Hypercalcemia managed with aggressive hydration, loop diuretics, bisphosphonates, or calcitonin

B. Pulmonary Type SCCO

Resembles small cell carcinoma of the lung (neuroendocrine)
Occurs in postmenopausal women
Associated with surface epithelial carcinoma (often endometrioid)
IHC: positive for neuroendocrine markers (synaptophysin, chromogranin, NSE)
Not associated with hypercalcemia
SMARCA4 mutations NOT present

Summary Table: Key Differentiating Features

Feature	SCCOHT	Pulmonary Type
Age	Young (~24 yr)	Postmenopausal
Hypercalcemia	~66%	No
SMARCA4 mutation	Yes (IHC: BRG1 loss)	No
Neuroendocrine markers	Negative	Positive
Associated tumor	None	Endometrioid carcinoma
Proposed reclassification	Ovarian rhabdoid tumor	Neuroendocrine carcinoma

Sources:

Robbins, Cotran & Kumar - Pathologic Basis of Disease (Robbins 10th Ed.), Chapter 22 - Ovarian Tumors, pp. 940-950
Berek & Novak's Gynecology, Chapter on Small Cell Carcinoma, p. 2406

Please include latest WHO classification

Searching the Web

WHO 2020 5th edition classification ovarian tumors female genital tract complete list

Searching PubMed

WHO classification ovarian tumors 2020 female genital tract

Finding Sources

Reading Web Page

https://www.mdpi.com/2075-4418/11/4/697

Reading Article

PMID: 34996131

Reading Web Page

https://schaberg.faculty.ucdavis.edu/wp-content/uploads/site…

Searching the Web

WHO 2020 ovarian tumors classification changes seromucinous removed mesonephric-like added SCCOHT SMARCA4 complete table

I now have all the material needed. Here is the comprehensive updated answer with the WHO 2020 (5th Edition) Classification.

WHO 2020 Classification of Ovarian Tumors + Advances in Epithelial Ovarian Tumors & SCCO

MD Pathology - 10 Marks

I. WHO 2020 (5th EDITION) COMPLETE CLASSIFICATION OF OVARIAN TUMORS

The WHO Classification of Tumours of the Female Genital Tract, 5th Edition (2020) (IARC, Lyon) is the current authoritative reference. It replaced the 4th edition (2014) and introduced significant updates integrating morphology, immunohistochemistry, and molecular data.

A. SURFACE EPITHELIAL TUMORS

1. Serous Tumors

Grade	Entities
Benign	Serous cystadenoma, serous adenofibroma, serous cystadenofibroma
Borderline	Serous borderline tumor (atypical proliferative serous tumor) - typical and micropapillary/cribriform variants
Malignant	Low-grade serous carcinoma (LGSC) - separate entity from 4th ed.
Malignant	High-grade serous carcinoma (HGSC)

Key 2020 change: LGSC and HGSC are now firmly recognized as two completely separate diseases with different origins, mutations, and treatment responses.

2. Mucinous Tumors

Benign: Mucinous cystadenoma, mucinous adenofibroma
Borderline: Mucinous borderline tumor (intestinal type; endocervical-type seromucinous borderline tumor moved separately)
Malignant: Mucinous carcinoma

3. Endometrioid Tumors

Benign: Endometrioid cystadenoma, endometrioid adenofibroma
Borderline: Endometrioid borderline tumor
Malignant: Endometrioid carcinoma (now includes former "seromucinous carcinoma" as a subtype)

4. Clear Cell Tumors

Benign: Clear cell cystadenoma, clear cell adenofibroma
Borderline: Clear cell borderline tumor
Malignant: Clear cell carcinoma

5. Brenner Tumors (Transitional Cell)

Benign Brenner tumor
Borderline Brenner tumor
Malignant Brenner tumor

6. Seromucinous Tumors (Retained for benign/borderline; carcinoma removed)

Benign: Seromucinous cystadenoma, seromucinous adenofibroma
Borderline: Seromucinous borderline tumor
Seromucinous carcinoma REMOVED from 2020 edition - reclassified as endometrioid carcinoma

7. NEW in 2020: Mesonephric-like Adenocarcinoma

New entity added; associated with endometriosis; KRAS mutations; IHC: TTF1+, GATA3+, ER-/PR-/WT1-

8. Undifferentiated and Dedifferentiated Carcinoma

Undifferentiated: no specific line of differentiation
Dedifferentiated: undifferentiated component with abrupt transition to differentiated (usually endometrioid) component

9. Mixed Carcinoma (Reintroduced in 2020)

Composed of two or more distinct histologic types, each comprising ≥10% of the tumor

10. Carcinosarcoma (Malignant Mixed Mesodermal Tumor / MMMT)

Reclassified as a dedifferentiated carcinoma (not a mixed tumor); arises via epithelial-mesenchymal transition (EMT)

B. SEX CORD-STROMAL TUMORS

Pure Stromal Tumors:

Fibroma (NOS; cellular fibroma)
Thecoma (NOS; luteinized thecoma)
Fibrothecoma
Sclerosing stromal tumor
Microcystic stromal tumor (new recognition)
Leydig cell tumor
Steroid cell tumor NOS
Fibrosarcoma (rare, malignant)

Pure Sex Cord Tumors:

Adult granulosa cell tumor (AGCT) - FOXL2 mutation (C134W) pathognomonic
Juvenile granulosa cell tumor (JGCT)
Sertoli cell tumor

Mixed Sex Cord-Stromal Tumors:

Sertoli-Leydig cell tumors (SLCT) - DICER1 mutations in ~60%
Gynandroblastoma
Sex cord tumor with annular tubules (SCTAT) - associated with Peutz-Jeghers syndrome

C. GERM CELL TUMORS

Tumor	Key Feature
Dysgerminoma	Ovarian counterpart of seminoma; OCT3/4+, NANOG+, KIT mutations; isochromosome 12p
Yolk sac tumor (endodermal sinus tumor)	AFP+, SALL4+; Schiller-Duval bodies
Embryonal carcinoma	CD30+, OCT4+; rare in pure form
Non-gestational choriocarcinoma	β-hCG+; very rare pure ovarian
Immature teratoma	Graded 1-3 by quantity of immature neuroepithelium
Mature teratoma (dermoid cyst)	Most common ovarian tumor overall
Monodermal teratoma	Struma ovarii (thyroid tissue); carcinoid
Mixed germ cell tumor	Two or more germ cell components

D. MISCELLANEOUS TUMORS (Category reorganized in 2020)

This category now contains entities that do not fit the above groups:

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) - SMARCA4 mutations; now under miscellaneous, not epithelial
Small cell carcinoma of the ovary, pulmonary type - neuroendocrine
Wilms tumor (rare)
Paraganglioma
Solid pseudopapillary neoplasm
Hepatoid carcinoma
Primary ovarian melanoma

Key 2020 change: SCCOHT is now placed under Miscellaneous tumors, not epithelial tumors, reflecting its rhabdoid/SMARCA4-mutant identity. [McCluggage et al., Histopathology 2022, PMID 34996131]

E. MESOTHELIAL TUMORS

Adenomatoid tumor
Mesothelioma (rare; peritoneal origin)

F. SOFT TISSUE TUMORS

Myxoma
Leiomyoma (rare)

G. LYMPHOID AND MYELOID TUMORS

Lymphomas (diffuse large B-cell most common)
Myeloid sarcoma

H. METASTATIC TUMORS TO THE OVARY (~5-6% of all ovarian tumors)

Primary Site	Features
Stomach (Krukenberg tumor)	Bilateral; signet ring cells; mucin-secreting cells in cellular stroma
Colorectal / Appendiceal	Bilateral; mucinous; CK7-/CK20+
Breast	Bilateral; lobular > ductal; ER/PR+
Endometrial / Tubal	Direct spread; endometrioid type
Cervix	Rare (<1%)
Appendix	Pseudomyxoma peritonei

II. KEY CHANGES: WHO 2020 vs WHO 2014 (4th Edition)

Feature	WHO 2014 (4th Ed)	WHO 2020 (5th Ed)
Serous carcinoma split	Recognized but less defined	LGSC and HGSC firmly = two separate diseases
Seromucinous carcinoma	Listed as distinct entity	Removed - subsumed into endometrioid carcinoma
Mesonephric-like adenocarcinoma	Not recognized	Newly added
Mixed carcinoma	Not separately listed	Reintroduced (≥2 components, each ≥10%)
SCCOHT	Listed under epithelial tumors/miscellaneous	Firmly placed in Miscellaneous, linked to SMARCA4/rhabdoid
Molecular data	Limited	Integrated into diagnostic criteria
Site of origin for HGSC	Ovary	Fallopian tube is primary site for most HGSCs (via STIC)
Carcinosarcoma	Mixed tumor	Reclassified as dedifferentiated carcinoma (EMT-derived)
IHC algorithms	Limited	Detailed IHC panels for each histotype

III. FIVE MAIN TYPES OF OVARIAN CARCINOMA (WHO 2020 Emphasis)

The 2020 edition emphasizes that these are 5 completely distinct diseases:

Type	Frequency	Origin	Key Mutation	IHC Profile
HGSC	70%	Fallopian tube fimbria (STIC)	TP53 (>96%), BRCA1/2 (15-25%)	PAX8+, WT1+, p53 mutant, ER+/-
Endometrioid	10%	Endometriosis	ARID1A, PIK3CA, CTNNB1	PAX8+, WT1-, p53 wt, PR+
Clear cell	6-10%	Endometriosis	ARID1A, PIK3CA	PAX8+, NapsinA+, WT1-, HNF1β+
LGSC	5%	Serous borderline tumor	KRAS, BRAF, NRAS	PAX8+, WT1+, p53 wt, ER+
Mucinous	3-4%	Brenner tumor/teratoma/de novo	KRAS	CK20+, CDX2+, WT1-, ER-

IV. ADVANCES IN EPITHELIAL OVARIAN TUMORS (2020 onwards)

Fallopian tube origin confirmed for HGSC: WHO 2020 introduced specific criteria for site assignment (tubal, ovarian, tubo-ovarian, peritoneal). By these criteria, 80% of HGSC are of tubal origin. Peritoneal primary requires absence of STIC and no ovarian involvement.
Molecular-morphologic integration: Each histotype now has a defined IHC panel and molecular profile (see table above) as part of routine diagnosis - not just research.
PARP inhibitors: Olaparib, niraparib, rucaparib approved as maintenance in BRCA-mutated/HRD-positive HGSC after platinum response. Bevacizumab (anti-VEGF) for frontline and recurrent disease.
TCGA molecular subtypes of HGSC - Immunoreactive, Differentiated, Proliferative, Mesenchymal - with prognostic/predictive implications.
Seromucinous carcinoma reclassification: Abolished as a distinct entity; now endometrioid carcinoma subtype.
Mesonephric-like carcinoma: Newly recognized; arises from Müllerian epithelium with mesonephric differentiation; associated with endometriosis; IHC: TTF1+, GATA3+, CD10 (luminal), PAX8+; ER/PR/WT1 negative.

V. SMALL CELL CARCINOMA OF THE OVARY (SCCO) - WHO 2020 Update

A. Hypercalcemic Type (SCCOHT) - Under Miscellaneous in 2020 WHO

Feature	Detail
WHO 2020 placement	Miscellaneous tumors (not epithelial)
Age	Mean 24 years (range 2-46 years)
Laterality	Usually unilateral
Hypercalcemia	~66% (paraendocrine)
Molecular hallmark	Germline or somatic SMARCA4 mutations (SWI/SNF chromatin remodeling)
IHC	Loss of BRG1 (SMARCA4) expression - diagnostic; INI1 retained
Relationship	Proposed reclassification as ovarian rhabdoid tumor
Prognosis	Poor; 5-year OS ~16%; most die within 2 years
Treatment	Surgery + platinum ± radiation; rhabdoid tumor regimens under investigation

B. Pulmonary Type SCCO

Feature	Detail
Age	Postmenopausal
Association	Often with surface epithelial carcinoma (endometrioid)
IHC	Synaptophysin+, Chromogranin+, NSE+
SMARCA4	Normal (retained BRG1)
Hypercalcemia	Absent

VI. QUICK SUMMARY TABLE: COMPLETE OVARIAN TUMOR CLASSIFICATION (WHO 2020)

OVARIAN TUMORS (WHO 2020, 5th Edition)
│
├── A. SURFACE EPITHELIAL TUMORS
│   ├── Serous (benign / borderline / LGSC / HGSC)
│   ├── Mucinous (benign / borderline / carcinoma)
│   ├── Endometrioid (benign / borderline / carcinoma) [includes former seromucinous Ca]
│   ├── Clear cell (benign / borderline / carcinoma)
│   ├── Brenner/Transitional (benign / borderline / malignant)
│   ├── Seromucinous (benign / borderline only — no carcinoma)
│   ├── Mesonephric-like adenocarcinoma [NEW 2020]
│   ├── Undifferentiated / Dedifferentiated carcinoma
│   ├── Mixed carcinoma [NEW 2020]
│   └── Carcinosarcoma (reclassified as dedifferentiated Ca)
│
├── B. SEX CORD-STROMAL TUMORS
│   ├── Pure stromal: Fibroma, Thecoma, Sclerosing stromal tumor, Leydig cell, Steroid cell
│   ├── Pure sex cord: AGCT, JGCT, Sertoli cell tumor
│   └── Mixed: SLCT, Gynandroblastoma, SCTAT
│
├── C. GERM CELL TUMORS
│   ├── Dysgerminoma
│   ├── Yolk sac tumor
│   ├── Embryonal carcinoma
│   ├── Non-gestational choriocarcinoma
│   ├── Teratoma (Immature / Mature / Monodermal)
│   └── Mixed germ cell tumor
│
├── D. MISCELLANEOUS TUMORS
│   ├── SCCOHT (SMARCA4-mutant) [moved from epithelial]
│   ├── SCCO, pulmonary type
│   ├── Wilms tumor, paraganglioma, hepatoid Ca, etc.
│
├── E. MESOTHELIAL TUMORS
├── F. SOFT TISSUE TUMORS
├── G. LYMPHOID AND MYELOID TUMORS
└── H. METASTATIC TUMORS (Krukenberg, colorectal, breast, etc.)

Sources:

WHO Classification of Tumours of the Female Genital Tract, 5th ed. (IARC, Lyon, 2020)
McCluggage WG et al. - Key changes in WHO 5th edition, Histopathology 2022 (PMID 34996131)
De Leo A et al. - New WHO 2020 ovarian carcinoma classification, Diagnostics 2021 (PMID 33919741)
Robbins, Cotran & Kumar - Pathologic Basis of Disease (10th Ed.), Chapter 22

Who latest classification and advances in epithelial ovarian tumor and small cell carcinoma of ovary, complete classification of ovarian tumors Pathogenesis morphology md pathology 10 marks

Based on our previous detailed research and the WHO 2020 5th Edition, here is the complete, exam-ready 10-mark answer:

Ovarian Tumors: WHO 2020 Classification, Epithelial Tumors & Small Cell Carcinoma

MD Pathology — 10 Marks

I. WHO 2020 (5th EDITION) — COMPLETE CLASSIFICATION OF OVARIAN TUMORS

(WHO Classification of Tumours of the Female Genital Tract, 5th Ed., IARC Lyon, 2020)

Ovarian neoplasms arise from three main cell lineages:

Surface/Müllerian epithelium (and endometriosis)
Germ cells (yolk sac-derived, pluripotent)
Sex cord-stromal cells (endocrine precursors)

A. SURFACE EPITHELIAL TUMORS (~65%)

1. Serous Tumors

Benign: Serous cystadenoma, serous adenofibroma, serous cystadenofibroma
Borderline: Serous borderline tumor (typical and micropapillary/cribriform variants)
Malignant:
- Low-grade serous carcinoma (LGSC)
- High-grade serous carcinoma (HGSC)

LGSC and HGSC are now firmly recognized as two entirely separate diseases in WHO 2020.

2. Mucinous Tumors

Benign: Mucinous cystadenoma, mucinous adenofibroma
Borderline: Mucinous borderline tumor
Malignant: Mucinous carcinoma

3. Endometrioid Tumors

Benign: Endometrioid cystadenoma, endometrioid adenofibroma
Borderline: Endometrioid borderline tumor
Malignant: Endometrioid carcinoma (now includes former "seromucinous carcinoma")

4. Clear Cell Tumors

Benign: Clear cell cystadenoma, clear cell adenofibroma
Borderline: Clear cell borderline tumor
Malignant: Clear cell carcinoma

5. Brenner (Transitional Cell) Tumors

Benign Brenner tumor
Borderline Brenner tumor
Malignant Brenner tumor

6. Seromucinous Tumors (benign/borderline retained; carcinoma REMOVED)

Benign: Seromucinous cystadenoma, seromucinous adenofibroma
Borderline: Seromucinous borderline tumor
~~Seromucinous carcinoma~~ — Abolished in 2020; reclassified as endometrioid carcinoma

7. Mesonephric-like Adenocarcinoma (NEW in 2020)

New entity; tubular/glandular/slit-like architecture; associated with endometriosis
IHC: TTF1+, GATA3+, CD10 (luminal)+; ER/PR/WT1 negative; KRAS mutations

8. Undifferentiated and Dedifferentiated Carcinoma

Undifferentiated: no specific line of differentiation
Dedifferentiated: undifferentiated component with abrupt transition to differentiated (endometrioid) component

9. Mixed Carcinoma (Reintroduced 2020)

Two or more distinct histologic types, each comprising ≥10% of the tumor

10. Carcinosarcoma (MMMT)

Reclassified as dedifferentiated/metaplastic carcinoma derived via epithelial-mesenchymal transition (EMT); not a true mixed tumor

B. SEX CORD-STROMAL TUMORS (~8%)

Pure Stromal:

Fibroma (NOS; cellular fibroma), Thecoma (NOS; luteinized), Fibrothecoma
Sclerosing stromal tumor, Microcystic stromal tumor
Leydig cell tumor, Steroid (lipid) cell tumor NOS, Fibrosarcoma

Pure Sex Cord:

Adult granulosa cell tumor (AGCT) — FOXL2 C134W mutation pathognomonic
Juvenile granulosa cell tumor (JGCT)
Sertoli cell tumor

Mixed Sex Cord-Stromal:

Sertoli-Leydig cell tumor (SLCT) — DICER1 mutations ~60%
Gynandroblastoma
Sex cord tumor with annular tubules (SCTAT) — associated with Peutz-Jeghers syndrome

C. GERM CELL TUMORS (~15-20%)

Tumor	Key Feature
Dysgerminoma	OCT3/4+, NANOG+, KIT mutations; i(12p); ovarian counterpart of seminoma
Yolk sac tumor	AFP+, SALL4+; Schiller-Duval bodies
Embryonal carcinoma	CD30+, OCT4+; rare in pure form
Non-gestational choriocarcinoma	β-hCG+; very rare
Immature teratoma	Graded 1-3 by immature neuroepithelium
Mature teratoma (dermoid cyst)	Most common ovarian tumor overall
Monodermal teratoma	Struma ovarii (thyroid); primary ovarian carcinoid
Mixed germ cell tumor	Two or more components

D. MISCELLANEOUS TUMORS (Reorganized in 2020)

Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) — SMARCA4-mutant; moved here from epithelial category
Small cell carcinoma of the ovary, pulmonary type
Wilms tumor (rare)
Paraganglioma, hepatoid carcinoma, solid pseudopapillary neoplasm

E. MESOTHELIAL TUMORS

Adenomatoid tumor
Mesothelioma (peritoneal)

F. SOFT TISSUE TUMORS

Myxoma, Leiomyoma (rare)

G. LYMPHOID AND MYELOID TUMORS

Lymphomas (DLBCL most common), Myeloid sarcoma

H. METASTATIC TUMORS TO THE OVARY (~5-6%)

Primary Site	Distinctive Feature
Stomach (Krukenberg tumor)	Bilateral; signet ring cells in cellular stroma
Colorectal / Appendiceal	Bilateral; CK7-/CK20+; pseudomyxoma peritonei (appendix)
Breast	Lobular > ductal; bilateral; ER/PR+
Endometrium / Fallopian tube	Direct spread; endometrioid type
Cervix	Rare (<1%)

II. KEY CHANGES: WHO 2020 vs 2014 (4th Edition)

Feature	WHO 2014	WHO 2020
Seromucinous carcinoma	Distinct entity	Removed → subsumed into endometrioid Ca
Mesonephric-like adenocarcinoma	Not recognized	Newly added
Mixed carcinoma	Not separately listed	Reintroduced (each component ≥10%)
LGSC vs HGSC	Recognized but less emphasized	Two completely separate diseases
SCCOHT	Listed under various categories	Firmly in Miscellaneous; SMARCA4 identity
Carcinosarcoma	Mixed tumor	Dedifferentiated carcinoma (EMT-derived)
Site of origin for HGSC	Ovary	Fallopian tube fimbria (STIC) — 80% of cases
Molecular data	Research-level	Integrated into routine diagnostic criteria

III. EPITHELIAL OVARIAN TUMORS — PATHOGENESIS & MORPHOLOGY

General Features

~80% of ovarian tumors are benign; malignant tumors peak at 45-65 years
Ovarian cancer = 3% of all female cancers; 5th commonest cancer death in women
Most arise from Müllerian-type epithelium (surface epithelium and endometriosis)

DUALISTIC (TYPE I / TYPE II) CARCINOGENESIS MODEL

Feature	TYPE I (Low-grade)	TYPE II (High-grade)
Growth	Slow, indolent	Rapid, aggressive
Precursor	Borderline tumor / endometriosis	STIC (serous tubal intraepithelial carcinoma)
Chromosomal instability	Low (microsatellite instability)	High (CIN)
Key mutations	KRAS, BRAF, ERBB2, PIK3CA, PTEN, ARID1A, CTNNB1	TP53 (>96%), BRCA1/BRCA2
Tumors included	LGSC, mucinous Ca, endometrioid Ca, clear cell Ca, Brenner	HGSC (70%), carcinosarcoma
Response to platinum	Moderate	Good initially; then resistance

A. SEROUS TUMORS — MORPHOLOGY

Benign Serous Cystadenoma

Gross: Thin-walled, unilocular or multilocular; smooth inner lining; clear serous fluid; unilateral (25% bilateral)
Micro: Single layer of ciliated columnar tubal-type (fallopian tube-like) epithelium; minimal atypia

Serous Borderline Tumor

Gross: Papillary projections on inner cyst surface
Micro: Epithelial stratification (2-3 layers), nuclear atypia, mitoses, papillary tufting — NO stromal invasion (key criterion)
Micropapillary/cribriform variant has slightly higher risk of peritoneal implants

Low-Grade Serous Carcinoma (LGSC)

Pathogenesis: Stepwise progression from cystadenoma → borderline tumor → LGSC; KRAS/BRAF/NRAS mutations; TP53 wild-type
Micro: Micropapillary architecture; small uniform cells with mild atypia; rare mitoses; psammoma bodies common; TP53 normal
Relatively resistant to platinum chemotherapy; MEK inhibitors (trametinib) show activity

High-Grade Serous Carcinoma (HGSC)

Pathogenesis: Arises from STIC in the fallopian tube fimbria (not the ovarian surface); TP53 mutation earliest event; BRCA1/BRCA2 in 15-25%; massive chromosomal instability
Gross: Partly solid, partly cystic; papillary excrescences; friable, tan-yellow with hemorrhage and necrosis; 65% bilateral
Micro: Complex papillary, glandular, or solid architecture; severely pleomorphic cells; numerous atypical mitoses; psammoma bodies (concentric calcifications, characteristic); TP53 mutation in >96% (IHC: diffuse strong positive or complete null)
IHC: PAX8+, WT1+, p53 mutant pattern, ER+/- (40%)
Spreads transcoelomically → peritoneum, omentum ("omental cake"), bowel serosa

Serous papillary cystadenocarcinoma — solid + cystic, papillary growth, necrosis, hemorrhage

B. MUCINOUS TUMORS — MORPHOLOGY

Benign Mucinous Cystadenoma:

Gross: Large (often enormous — largest benign ovarian tumors), multilocular; thick viscid mucin; smooth inner lining; 80% benign; 5% bilateral
Micro: Tall columnar mucin-secreting cells resembling endocervical (Müllerian) or intestinal epithelium with goblet cells

Mucinous Adenocarcinoma:

Micro: Glands with obvious stromal invasion; malignant columnar cells; must be distinguished from metastatic colonic adenocarcinoma (IHC: CK7+/CK20- favors primary ovarian; CK7-/CK20+ favors metastatic colorectal)
Pseudomyxoma peritonei: Massive mucinous ascites — almost always arises from appendiceal mucinous neoplasm, not primary ovarian

Mucinous cystadenoma (multilocular) alongside Brenner tumor (yellow-white solid) — bilateral ovarian neoplasms

C. ENDOMETRIOID CARCINOMA — MORPHOLOGY & PATHOGENESIS

Pathogenesis: Arises from endometriosis (endometrioma → atypical endometriosis → carcinoma); ARID1A mutations (loss of BAF250a), PIK3CA, CTNNB1 (β-catenin), PTEN; microsatellite instability in Lynch syndrome
15-20% associated with synchronous endometrial carcinoma (most are independent primaries)
Gross: Partly cystic, partly solid; chocolate-colored contents if arising from endometrioma; 40% bilateral
Micro: Tubular/glandular structures resembling proliferative endometrium; stratified non-mucinous columnar cells; squamous metaplasia/morules (common); WT1 negative (unlike HGSC), PR+ (80%)

D. CLEAR CELL CARCINOMA — MORPHOLOGY

Pathogenesis: Endometriosis → atypical endometriosis → clear cell carcinoma; ARID1A, PIK3CA mutations; relative resistance to platinum
Gross: Partly solid, partly cystic
Micro: Large cells with abundant clear cytoplasm (glycogen); "hobnail cells" projecting into cystic spaces; tubular, papillary, or solid architecture
IHC: NapsinA+, HNF1β+, PAX8+; WT1- and ER- (distinguishes from HGSC)

E. BRENNER TUMOR — MORPHOLOGY

Gross: Solid, firm, whitish-grey, usually small and incidental; commonly associated with ipsilateral mucinous cystadenoma
Micro: Nests of transitional (urothelial-like) epithelium embedded in dense fibrous stroma; characteristic longitudinal nuclear grooves ("coffee-bean" nuclei); cells resemble Walthard cell rests; cystic spaces filled with mucinous or eosinophilic secretion

IV. ADVANCES IN EPITHELIAL OVARIAN TUMORS (2020 Onwards)

Fallopian tube as primary site of HGSC: WHO 2020 formalized criteria for site assignment. ~80% of HGSC now classified as tubal in origin via STIC. Risk-reducing bilateral salpingectomy (even in average-risk women) is now a clinical strategy.
Molecular diagnostic integration: Each histotype has a validated IHC panel + molecular signature used in routine diagnosis:

Histotype	PAX8	WT1	p53	NapsinA	PR
HGSC	95%	95%	Mutant (>95%)	1%	40%
LGSC	95%	99%	Wild-type	0%	60%
Endometrioid	80%	10%	Wild-type (15% mutant)	5%	80%
Clear cell	95%	1%	Wild-type	95%	5%
Mucinous	40%	0%	60% mutant	0%	0%

PARP inhibitors: Olaparib, niraparib, rucaparib approved as maintenance therapy in BRCA-mutated/HRD-positive HGSC after platinum response — targeted therapy based on WHO 2020 molecular classification.
HRD (Homologous Recombination Deficiency): Broader biomarker beyond BRCA mutations; HRD-positive tumors (even BRCA wild-type) respond to platinum + PARP inhibitors.
TCGA molecular subtypes of HGSC: Immunoreactive, Differentiated, Proliferative, and Mesenchymal — prognostic and predictive significance.
Bevacizumab (anti-VEGF): Approved frontline + recurrent HGSC maintenance.
Seromucinous carcinoma abolished: Now classified as endometrioid carcinoma based on IHC (ER+, PR+, PAX8+, WT1-) and molecular similarity (ARID1A, PIK3CA).
DICER1 syndrome: Germline DICER1 mutations predispose to SLCT, cystic nephroma, pleuropulmonary blastoma — included in WHO 2020.

V. SMALL CELL CARCINOMA OF THE OVARY (WHO 2020)

A. Hypercalcemic Type (SCCOHT) — Now under Miscellaneous

Feature	Detail
WHO 2020 category	Miscellaneous tumors (NOT epithelial)
Age	Mean 24 years (range 2-46 yrs)
Laterality	Unilateral
Hypercalcemia	~66% (paraendocrine — PTHrP-like mechanism)
Spread at diagnosis	~50% beyond ovary
Molecular hallmark	Germline or somatic SMARCA4 mutation (SWI/SNF chromatin remodeling complex)
IHC	Loss of BRG1 (SMARCA4) expression; INI1 (SMARCB1) retained
Proposed reclassification	Ovarian rhabdoid tumor (similar SMARCA4 mutations to rhabdoid tumors at other sites)
Prognosis	Poor: 5-year OS ~16%; most die within 2 years

Gross: Large solid unilateral mass; hemorrhage and necrosis

Micro: Small cells with scanty cytoplasm, hyperchromatic nuclei in diffuse sheets; ~50% have a large cell component with prominent nucleoli; follicle-like spaces may be present; IHC confirms BRG1 loss

Management:

Surgery (aggressive staging)
Platinum-based chemotherapy ± radiation
Rhabdoid tumor-based aggressive regimens under investigation (given SMARCA4 identity)
Hypercalcemia control: hydration, loop diuretics, bisphosphonates, calcitonin

B. Pulmonary Type SCCO

Feature	Hypercalcemic Type	Pulmonary Type
Age	Young (~24 yr)	Postmenopausal
Hypercalcemia	~66%	Absent
SMARCA4/BRG1	Mutated/lost	Normal
Neuroendocrine markers	Negative	Synaptophysin+, Chromogranin+, NSE+
Associated tumor	None	Endometrioid carcinoma
WHO 2020 category	Miscellaneous	Miscellaneous
Proposed identity	Ovarian rhabdoid tumor	Neuroendocrine carcinoma

VI. FREQUENCY TABLE (Robbins/Cotran 10th Ed.)

Type	% of Malignant Tumors	% Bilateral
Serous (HGSC + LGSC)	47%	Malignant 65%, Borderline 30%, Benign 25%
Endometrioid	20%	40%
Undifferentiated	10%	-
Clear cell	6-10%	40%
Mucinous	3%	<5%
Granulosa cell	5%	5%
Teratoma	1%	Rare
Metastatic	5%	>50%

QUICK MEMORY AID — WHO 2020 NEW ADDITIONS/CHANGES

"SMART MD"

Seromucinous carcinoma — Removed

Mesonephric-like adenocarcinoma — Added

All serous carcinomas — LGSC and HGSC as two separate diseases

Reclassified Carcinosarcoma — dedifferentiated carcinoma (EMT)

Tubal origin of HGSC — STIC confirmed as precursor

Mixed carcinoma — Reintroduced

Dedifferentiated carcinoma — separate entity

References:

WHO Classification of Tumours of the Female Genital Tract, 5th Ed. (IARC, Lyon, 2020)
McCluggage WG, Singh N, Gilks CB - Key changes in WHO 5th edition, Histopathology 2022 (PMID 34996131)
De Leo A et al. - Integrated morphologic & molecular analysis per WHO 2020, Diagnostics 2021 (PMID 33919741)
Robbins, Cotran & Kumar — Pathologic Basis of Disease, 10th Ed., Chapter 22

This is a shared conversation. Sign in to Orris to start your own chat.